First-line systemic treatment options for advanced renal cell carcinoma
Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma, Page: 269-292
2023
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
The treatment of advanced clear cell renal cell carcinoma (ccRCC) has undergone significant changes over the last two decades, particularly with the development of antiangiogenic therapies, in particular vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). The first-line therapeutic paradigm is dominated by combination therapies of ICI/ICI or TKI/ICI, although high-dose interleukin (IL)-2 or individual TKIs are still used in limited circumstances. This chapter provides a historical overview with a focus on currently FDA approved ICI combinations: ipilimumab/nivolumab, axitinib/pembrolizumab, axitinib/avelumab, cabozantinib/nivolumab, and lenvatinib/pembrolizumab. Challenges and approaches to therapeutic choices are also explored.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85198342224&origin=inward; http://dx.doi.org/10.1007/978-3-031-40901-1_12; https://link.springer.com/10.1007/978-3-031-40901-1_12; https://dx.doi.org/10.1007/978-3-031-40901-1_12; https://link.springer.com/chapter/10.1007/978-3-031-40901-1_12
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know